


# HemCon – More Than a Pioneer in Hemostasis Now a Powerful Barrier Against MRSA



## **HOSPITAL WIDE BLEEDING CARE IN:**

- Diagnostic & Interventional vascular access and percutaneous catheter access sites
- Emergency Procedures
- Acute Wounds Management
- Hemodialysis Bleeding
- ICU/CICU and bleeding from the skin at percutaneous needle access sites



**HemCon**  
MEDICAL TECHNOLOGIES INC

*HemCon Medical Technologies, Inc. originally developed hemorrhage control bandages for use on the battlefield, providing rapid control of moderate to severe external (arterial) hemorrhaging, as well as providing an antibacterial barrier. The real-time benefits of these revolutionary bandages have helped save hundreds of lives, and therefore remain a top choice hemostat for the military worldwide.*

The antibacterial properties of chitosan have been investigated using an in vitro methodology in which the antibacterial activities of chitosan were measured against a wide range of bacteria. Results demonstrated that chitosan increased permeability of the inner and outer membranes and ultimately disrupted the bacterial cell membranes, releasing their contents. HemCon dressings provide an antibacterial barrier against a wide range of gram positive and gram negative organisms.

### Percent and log reductions\* of organisms after exposure to dressing

Organism	Gram Stain	Percent Reduction	Log Reduction
<i>Escherichia coli</i> ATCC 8739	-	>99.99	>5.2
<i>Klebsiella pneumoniae</i> ATCC 4352	-	>99.99	>5.3
<i>Streptococcus pyogenes</i> ATCC 19615	+	>99.99	>5.5
<b><i>Staphylococcus aureus</i> (MRSA) ATCC 33591</b>	<b>+</b>	<b>&gt;99.99</b>	<b>&gt;4.0</b>
<i>Staphylococcus epidermidis</i> ATCC 12228	+	>99.99	>5.2
<b><i>Acinetobacter baumannii</i> ATCC 15308</b>	<b>-</b>	<b>&gt;99.99</b>	<b>&gt;4.2</b>
<i>Pseudomonas aeruginosa</i> ATCC 9027	-	99.99	>4.3
<b><i>Enterococcus faecalis</i> (VRE) ATCC 51299</b>	<b>+</b>	<b>&gt;99.99</b>	<b>&gt;5.4</b>
<i>Enterococcus faecalis</i> ATCC 700802	+	>99.99	>5.4
<i>Serratia marcescens</i> ATCC 13880	-	99.99	5.0
<i>Stenotrophomonas maltophilia</i> ATCC 12714	-	>99.99	>5.1
<i>Streptococcus mutans</i> ATCC 25175	+	>99.99	>5.2
<i>Clostridium difficile</i> ATCC 9689	+	>99.99	>5.6
<i>Streptococcus pneumoniae</i> ATCC 10015	+	99.99	5.8
<i>Shigella species</i> ATCC 11126	-	>99.99	>5.4
<i>Salmonella choleraesuis</i> ATCC 10708	-	>99.99	>5.1
<i>Enterobacter aerogenes</i> ATCC 13048	-	>99.99	>5.0
<i>Proteus mirabilis</i> ATCC 4630	-	>99.99	>5.2
<i>Proteus vulgaris</i> ATCC 12454	-	>99.99	>4.8
<i>Citrobacter freundii</i> ATCC 8090	-	>99.99	>4.3
<i>Enterobacter cloacae</i> ATCC 13047	-	>99.99	>4.2
<i>Moraxella catarrhalis</i> ATCC 8193	-	>99.99	>4.1
<i>Micrococcus luteus</i> ATCC 49732	+	99.99	4.9
<i>Vibrio cholerae</i> ATCC 11558	-	>99.99	>4.9

\* Percent/log reduction refers to the percentage/log reduction in organisms at 24 hours vs. 0 hours exposure to the dressing. Only single strains of most species mentioned have been studied. The clinical significance of these findings is unknown.



**HemCon**  
MEDICAL TECHNOLOGIES INC

10575 SW Cascade Avenue, Suite 130, Portland, OR 97223-4363

Toll Free (U.S. & Canada) 877.247.0196

Phone: +1.503.245.0459 • Fax: +1.971.223.1000

www.hemcon.com • info@hemcon.com